Targeted DNA sequencing of high-grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression.

High-grade serous ovarian carcinoma (HGSC) is the most common subtype of ovarian cancer and is among the most fatal gynecological malignancies worldwide, due to late diagnosis at advanced stages and frequent therapy resistance. In 47 HGSC patients, we assessed somatic and germline genetic variability of a custom panel of 144 known or suspected HGSC-related genes by high-coverage targeted DNA sequencing to identify the genetic determinants associated with resistance to platinum-based therapy. In the germline, the most mutated genes were DNAH14 (17%), RAD51B (17%), CFTR (13%), BRCA1 (11%), and RAD51 (11%).

Importance of basal fibroblast growth factor levels in patients with ovarian tumor.

Objective: Evaluation of importance of serum levels of basic fibroblast growth factor (bFGF) in patients with ovarian cancer, patients with border-line ovarian tumor, patients with benign ovarian cyst and women with normal ovarian tissue.

Design: Prospective clinical study.

Setting: Department of Gynecology and Obstetrics, Charles University, Faculty of Medicine in Hradec Kralove and University Hospital Hradec Kralove.

Aberrant methylation of PCDH17 gene in high-grade serous ovarian carcinoma.

Background: Aberrant DNA methylation of protocadherins (PCDHs) has been associated with development and progression of various types of cancer. It could represent possible direction in the search for critically needed tumor biomarkers for ovarian cancer.

Objective: To investigate methylation of δ2 group of non-clustered PCDHs in high-grade serous ovarian carcinoma (HGSOC) tissue in comparison with control tissue.

[Expression of ATP-binding Cassette Proteins Pgp, MRP1, and MRP3 in Malignant and Benign Ovarian Lesions].

Background: This study was designed to compare the expression of PgP (P-glycoprotein), MRP1 (multidrug related protein), and MRP3 in ovarian cancer patients, patients with benign ovarian tumors, and healthy women, and to evaluate the correlation between the expression of ATP-binding cassette proteins Pgp, MRP1, and MRP3 with stage, grade, and histological type.

Patients And Methods: Tissue specimens from 212 women who underwent surgery at the Department of Obstetrics and Gynecology at University Hospital Hradec Králové were subjected to immunohistochemical staining for Pgp, MRP1, and MRP3.

Results: The expression of Pgp and MRP1 was higher in ovarian tumor cells than in the cells lining the ovarian cyst.

[Prognostic significance of Pgp, MRP1, and MRP3 in ovarian cancer patients].

Objective: To evaluate the correlation of resistance proteins Pgp (P-glycoprotein), MRP1 (Multidrug Related Protein, Multidrug Resistance-Associated Protein) and MRP3 with clinical - pathological factors and to find the clinical outcome of these data in ovarian cancer patients.

Design: Prospective study.

Setting: Department of Gynecology and Obstetrics, Charles University in Prague, Faculty of Medicine in Hradec Králové, University Hospital Hradec Králové.

Comparative study of various subpopulations of cytotoxic cells in blood and ascites from patients with ovarian carcinoma.

Aim Of The Study: A number of observations have indicated that the immune system plays a significant role in patients with epithelial ovarian cancer (EOC). In cases of EOC, the prognostic significance of tumour infiltrating lymphocytes has not been clearly explained yet. The aim is to determine the phenotype and activation molecules of cytotoxic T cell and NK cell subpopulations and to compare their representation in malignant ascites and peripheral blood in patients with ovarian cancer.

Clinical significance of the resistance proteins LRP, Pgp, MRP1, MRP3, and MRP5 in epithelial ovarian cancer.

Objective: This study aimed to evaluate the correlation between the expressions of lung resistance protein (LRP), P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP)-1, MRP3, and MRP5 and histopathological parameters and clinical outcome, and to determine the predictive and prognostic value of these transport proteins in patients with ovarian cancer.

Methods: Tumor samples from 111 chemonaive patients with epithelial ovarian cancer who underwent primary surgery from 2006 to 2010 were immunohistochemically stained for LRP, Pgp, MRP1, MRP3, and MRP5 expressions.

Results: MRP1 expression was greater among patients with late disease than among patients with early stage ovarian cancer [International Federation of Gynecology and Obstetrics (FIGO) I + II, 71.

[Ultrasound staging of endometrial cancer - recommended methodology of examination].

The extent of the staging surgery in cases of histologically proven endometrial cancer depends on whether the tumor is of high risk or low risk for extrauterine spread and recurrence. There are several significant prognostic factors - histological subtype and grade of dediferentiation from preoperative biopsy and local stage of uterine involvement based on imaging methods. The depth of myometrial invasion and presence of cervical stromal infiltration (local staging) can be assessed by ultrasound with the overall accuracy comparable to that of magnetic resonance.

[Ultrasonic staging cervical cancer -a proposal for the standard procedure].

Objective: To develop guidelines for the ultrasound examination of cervical cancer, including a unified ultrasound terminology.

Subject: Original paper.

Setting: Gynecological Oncology Center, Department of Obstetrics and Gynecology, Masaryk University and General Faculty Hospital Brno, and Gynecological Oncology Center, Department of Obstetrics and Gynecology, Charles University in Prague - First Faculty of Medicine and General Faculty Hospital Prague.

[Drug resistance proteins LRP, Pgp, MRP1, MRP3 and MRP5 in ovarian cancer patients].

Objective: To evaluate the correlation of drug resistance proteins LRP (Lung Resistance Protein), Pgp (P-glycoprotein), MRP1 (Multidrug Related Protein, Multidrug Resistance-Associated Protein), MRP3 a MRP5 with clinical - pathological factors and to find the clinical outcome of these data in ovarian cancer patients.

Design: Prospective study.

Setting: Department of Obstetrics and Gynecology, Charles University in Prague, Faculty of Medicine and University Hospital Hradec Kralove.

[Hypersensitivity reactions to carboplatin and paclitaxel - our five-years experiences].

Objective: To analyze hypersensitivity reactions to carboplatin and paclitaxel in patients treated with systemic administration of chemotherapy (carboplatin and/or paclitaxel).

Design: Retrospective study.

Setting: Department of Obstetrics and Gynecology, Charles University in Prague, Faculty of Medicine and University Hospital Hradec Kralove.

[Can be considered the primary fallopian tube cancer an enigma at the beginning of the third millenium?].

Objective: To analyze differences between primary fallopian tube cancer and ovarian cancer.

Design: Overview study.

Setting: Department of Obstetrics and Gynecology, The Fingerland Department of Pathology, Department of Oncology and Radiotherapy, Faculty of Medicine and University Hospital Hradec Kralove.

[Proteins of resistance and drug resistance in ovarian carcinoma patients].

Background: To evaluate the correlation of resistance proteins LRP (Lung Resistance Protein), Pgp (P-glycoprotein), MRP (Multidrug Resistance-Associated Protein), MRP3 a MRP5 with stage, grade and histological type. To asses correlation of these resistance proteins with drug resistance/drug sensitivity in vitro by means of the MTT assay in ovarian cancer patients. To find the clinical outcome of these data.

[A new opportunity in ovarian cancer treatment].

Objective: Targeted treatment in ovarian cancer patients.

Design: Practical paper.

Setting: Department of Gynecology and Obstetrics, Medical Faculty Charles University, Prague and University Hospital, Hradec Králové.

[Vascular endothelial growth factor in ovarian cancer patients].

Objective: To compare plasma VEGF (vascular endothelial growth factor) levels in ovarian cancer patients, in patients with benign ovarian tumors and healthy women.

Design: Prospective study.

Setting: Department of Gynecology and Obstetrics, Medical Faculty Charles University, Prague and University Hospital, Hradec Králové.

[Primary drug resistance/sensitivity in vitro and clininical outcome in ovarian cancer patients].

Objective: To assay correlation between primary resistance/sensitivity in vitro by MTT test in solid tumor and ascitic fluid and clininical outcome in ovarian cancer patients.

Design: Prospective study.

Setting: Department of Gynecology and Obstetrics, Medical Faculty Charles University, Prague and University Hospital, Hradec Králové.

Lysophosphatidic acid (LPA)—a perspective marker in ovarian cancer.

To compare plasma lysophosphatidic acid (LPA) levels in ovarian cancer patients in women with benign ovarian tumors and in women with no ovarian pathology. We correlated clinico-pathological parameters with plasma LPA levels. Capillary electrophoresis with indirect ultraviolet detection was used to analyze the plasma LPA levels of 159 patients (81 patients with ovarian cancer, 27 women without ovarian or uterine pathologies, and 51 patients with benign ovarian tumors) during a 5-year period.

Chemoresistance testing of human ovarian cancer cells and its in vitro model.

Ovarian carcinoma represents the most common cause of death from gynecological malignancies in Europe and North America, being the third most frequent and the first as to the mortality. The standard chemotherapeutical regimen for ovarian cancer involves the administration of platinum derivate (carboplatin, cisplatin), in advanced stage is platinum derivate combined with paclitaxel. Introducing chemoresistance testing of ovarian tumour cells may help to choose optimal chemotherapeutic drug and customize the individual chemotherapeutical regimens in patients.

[Resistance/sensitivity in vitro in ovarian cancer patients].

Objective: To assay resistance/sensitivity by MTT test in solid tumor or ascitic fluid in ovarian cancer patients.

Design: Prospective study.

Setting: Department of Gynecology and Obstetrics, Medical Faculty Charles University, Prague and University Hospital, Hradec Králové.

Lysophosphatidic acid: an ovarian cancer marker.

Objective: To determine whether lysophosphatidic acid (LPA) can serve as an ovarian cancer marker, we compared plasma LPA levels in ovarian cancer patients, in women with no ovarian pathology, and in women with benign ovarian tumors. We determined the optimal plasma LPA level cutoff value and correlated clinicopathological parameters with plasma LPA levels.

Method: Capillary electrophoresis with indirect ultraviolet detection was used to analyze the plasma LPA levels of 133 patients (60 patients with ovarian cancer, 43 women without ovarian pathologies and 30 patients with benign ovarian tumors) during a three-year period.

[Chemoresistance/Chemosensitivity of ovarian cancer--a case report].

Objective: To describe chemoresistance and chemosensitivity of two ovarian cancer patients and influence on their medical outcome.

Settings: Department of Obstetrics and Gynecology, Medical Faculty Charles University Prague and University Hospital, Hradec Králové.

Subject And Method: A case report of two ovarian cancer patients with defined chemoresistance/chemosensitivity of their tumors.

Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.

Objective: Epithelial ovarian cancer (EOC) is the most common cause of death among gynecological malignancies in Europe and North America. Although the presence of tumor-infiltrating mononuclear cells has been documented in EOC, the association of tumor-infiltrating mononuclear cells with clinical outcome remains controversial. The aim of the present study was to investigate the prognostic significance of CD3+ tumor-infiltrating T lymphocytes (TIL) on overall survival of EOC patients.

[Lysophosphatidic acid in ovarian cancer patients].

Objective: To compare plasma lysophosphatidic acid (LPA) level in ovarian cancer patients and women without ovarian pathology.

Design: Prospective study.

Setting: Department of Gynecology and Obstetrics, University Hospital, Hradec Králové.

[Prognostic markers in ovarian carcinoma--retrospective study].

Ovarian carcinoma is one of the most common cancers in women. The high mortality is due mostly to the fact that the tumour is frequently diagnosed in advanced stages. The aim of our study was to find immunohistochemically detectable significant prognostic markers for invasive ovarian carcinoma.